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ABSTRACT   
The bromodomain and PHD finger-containing (BRPF) family are scaffolding proteins important for the 
recruitment of histone acetyltransferases of the MYST family to chromatin. Here we describe NI-57 
(16) as new pan-BRPF chemical probe of the bromodomain (BRD) of the BRPFs. Inhibitor 16 
preferentially bound the BRD of BRPF1 and BRD1 over BRPF3, whereas binding to BRD9 was 
weaker. 16 has excellent selectivity over non-class IV BRD proteins. Target engagement of BRPF1B 
and BRD1 with 16 was demonstrated in nanoBRET and FRAP assays. The binding of 16 to BRPF1B 
was rationalized through an X-ray co-crystal structure determination which showed a flipped binding 
orientation when compared to previous structures. We report studies that show 16 has functional 
activity in cellular assays by modulation of the phenotype at low molar concentrations in both cancer 
and inflammatory models. Pharmacokinetic data for 16 was generated in mouse with single dose 
administration showing favourable oral bioavailability.  
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INTRODUCTION 
Lysine acetylation is a key modification which, in combination with other posttranslational 
modifications, constitutes the epigenetic code, a complex language that is interpreted by protein 
interaction modules, so called reader domains that specifically interact with sequences harbouring 
these modifications.  Aberrant acetylation is a hallmark of many diseases and acetyl lysine reader 
domains have therefore emerged as potential targets for treatment.1,2   
Lysine acetylation is specifically recognized by bromodomains (BRD), a family of 61 diverse protein 
domains that all share a conserved helical fold comprising a left-handed bundle of four α helices (αZ, 
αA, αB, αC), linked by loop regions of variable length (ZA and BC loops).3 Despite this structural 
conservation, the sequence diversity within the BRD family is high facilitating the development of 
specific inhibitors. Furthermore, the deep and mainly hydrophobic acetyl-lysine binding sites in most 
BRDs have good predicted druggability4 and this property has been validated experimentally by the 
recent development of a large diversity of BRD inhibitors.2, 5  
The first potent BRD inhibitors have been developed against the BET family (BRD2, BRD3, BRD4, 
BRDT).6-10 The disease modifying properties of these inhibitors and their general availability resulted 
in a number of clinical studies, mainly in oncology.11 The success of pre-clinical BET inhibitors 
spurred the development of inhibitors outside this family which now covers most of the main BRD 
families5 including BRDs of BAZ2A/B,12,13 CREBBP/P300,14-16 SMARCA2/4,17,18 BRD9/7,19,20 PCAF,21 
ATAD222 as well as promiscuous inhibitors called bromosporines.23 In addition, inhibitors for members 
of the BRDs of the Bromodomain and Plant Homeodomain (PHD) Finger-containing (BRPF) family of 
proteins (BRPF1, BRPF2 (also termed BRD1) and BRPF3) have been identified.24-30 
  
  
 
 
Figure 1. Cartoon representation of BRPFs as part of the tetrameric MYST scaffolding complex along 
with ING5 and hEAF6. The BRPFs contain multiple chromatin reader domains. 
 
BRPF family members are scaffolding proteins that harbour a diversity of protein interaction domains 
including two N-terminal PHD domains linked by a Zn2+ knuckle (PZP [PHD–Zn knuckle–PHD] 
domain) (targeting unmodified sequences in histone H3), a BRD as well as a C-terminal PWWP 
domain binding to tri-methylated K36 in histone H3.31 The BRD in BRPF has been described to 
interact with a number of histone acetylation sites such as H2AK5ac, H4K12ac and H3K14ac.32 BRPF 
proteins are central scaffolds that recruit histone acetyl-transferases (HATs) of the MYST family 
assembling a chromatin complex that also contains the ING tumour suppressor and hEAF6 (an EPC-
associated protein) (Figure 1).33 The scaffolding function of BRPF proteins is required for substrate 
specificity of MYST HATs. Alternative scaffolding proteins of the JADE family that share the BRPF N-
terminus but lack the C-terminal bromo and PWWP domains direct MYST complexes towards the H4 
tail whereas the BRPF containing complexes are targeted to histone H3.34 MYST/BRPF2 complexes 
play important roles in the regulation of erythropoiesis. Deletion of the BRPF2 gene in mice for 
instance results in severe anaemia due to impaired foetal liver erythropoiesis.35 We recently 
demonstrated that the BRD in BRPF is required for differentiation of monocytes into bone resorbing 
osteoclasts suggesting important function of the acetyl-lysine reader function of BRPF/MYST 
regulating bone turnover.36 Therapeutic targeting of BRPF1 by small molecules may also be valuable 
in the myelomonocytic morphologic subtype of acute myeloid leukemia (AML).30  
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Chart 1. Chemical probes and inhibitors for the bromodomain of the BRPFs, TRIM24-BRPFs and 
BRPF2-TAF1. The 1,3-dimethyl benzimidazolone, which acts as a acetyl-lysine mimic, is shown within 
the blue box.  
Recent studies have identified the 1,3-dimethyl benzimidazolone template as binding to the BRD of 
BRPF1 and this core has been optimised to give three chemical probes as either the pan-BRPF BRD 
inhibitor OF-1,24 or as the selective BRPF1 BRD inhibitors PFI-425 and GSK685326 (Chart 1). The 1,3-
dimethyl benzimidazolone template has also been used to identify TRIM24-BRPF inhibitors such as 
  
 
IACS-957127 and others.28 BAY-299 is a potent inhibitor of BRPF2 and the second BRD of TAF1 and 
has been published with an inactive partner as a negative control.29 Although these inhibitors all share 
some common structural features with respect to their acetyl-lysine mimic, their pharmacology profiles 
and biopharmaceutical properties are quite different.  
The use of small molecule inhibitors as chemical probes to investigate the relationship between the 
target and disease is significantly enhanced when two structurally orthogonal chemical probes are 
employed. We reported the discovery of a BRD fragment hit which was optimized by structure guided 
design to NI-42 (15) as an inhibitor of the BRD of the BRPF proteins (Table 1).30 Compound 15 has 
an N-methylquinolin-2-one as the acyl-lysine mimic which offers a different secondary pharmacology 
fingerprint profile to the benzimidazolones. Quinolin-2-one 15 is a biased, potent inhibitor of the BRD 
of the BRPFs with good selectivity over non-class IV BRD proteins.  
Table 1. Selected properties of 15 
 
NI-42 (15) 
mw 353; clogP 2.5; tPSA 90 
BRPF1  KD (ITC) 40 nM 
BRPF2  KD (ITC) 210 nM 
BRPF3  KD (ITC) 940 nM 
BRD9  KD (ITC) 1130 nM  
 
Selectivity vs non-Class IV BRDs: 
∆Tm shift at 10 M  < 1 oC  
 
Our aims were to further explore the quinolin-2-one series and to design new small molecule 
inhibitors of the BRD of the BRPFs. Here we report detailed SAR studies that led to the discovery of a 
second generation chemical probe for the BRPFs with improved potency and selectivity over 15 which 
is suitable for cellular and in vivo studies. 
  
  
 
RESULTS AND DISCUSSION 
Chemistry. The general methods for the synthesis of the quinolin-2(1H)-one sulfonamides 1-42 are 
outlined in Schemes 1 and 2. The 6-amino quinolin-2(1H)-ones 43-55 were reacted with the 
appropriate sulfonyl chlorides 56 in the presence of base to give the corresponding sulfonamides 1-9, 
14-37 as previously described (Scheme 1).30 The amines 43-55 were generally prepared by published 
methods or the application of know procedures. The sulfonyl chlorides 56 were purchased from 
commercial sources or prepared by standard methods. The N-alkyl sulfonamides 38-42 were 
prepared from the corresponding N-H sulfonamides by deprotonation with NaH and reaction with the 
appropriate alkyl iodide 57. 
Scheme 1: General synthesis of sulfonamides 1-9, 14-42 
  
 
 
Amines 43-55, with H unless otherwise stated: 
43:   R1 = Me   
44:   R1 = R3 = Me 
45:   R1 = Me; R3 = Et 
46:   R1 = Me; R3 = iPr 
47:   R1 = Me; R4 = Me 
48:   R1 = Me; R5 = F 
49:   R1 = Me; R7 = OMe 
50:   R1 = Me; R7 = OEt 
51:   R1 = Me; R7 = OiPr 
52:   R1 = Me; R7 = F 
53:   R1 = Me; R3 = Me; R7 = OMe 
54:   R1 = Me; R3 = Me; R8 = F 
55:   R1 = R3 = Et 
 
 
 
  
  
 
Reversed sulfonamides 10-13 were prepared by an analogous reaction of quinolin-2-one-6-sulfonyl 
chloride 59 with the appropriate anilines 60 (Scheme 2). 
Scheme 2: Synthesis of 1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonyl chloride (59) and 10-13. 
 
Reagents and Conditions: (a) HSO3Cl, 95 oC, 77 %; (b) ArNH2 (60)(0.9 eq), pyridine (1.0 eq), 
CH2Cl2, rt, o/n, 39-79 %; (c) For 11: 2-Aminobenzonitrile (0.9 eq), pyridine (1.0 eq), DMAP (0.1 eq), 
CH2Cl2, reflux, o/n, 15 %; 
 
Screening Strategy. Compounds were screened for BRPF affinity by two complementary methods to 
develop SARs. Compounds were initially tested for BRPFs BRD binding (∆Tm) with a differential 
scanning fluorimetry (DSF) assay and then screened for inhibition (IC50) of BRPF BRD activity as 
measured by the BROMOscan biochemical assay (Tables 2-4). BRD9 and BRD4(BD1) were routinely 
used as BRD counter screens to establish evidence of selectivity in both the DSF and BROMOscan 
assays. In general, there was a good correlation between the DSF and BROMOscan data for these 
compounds with very similar trends in ranked order of affinities. Preferred compounds were then 
evaluated for selectivity against a panel of 47 BRDs by DSF and inhibition of BRPF BRD activity was 
confirmed by independent evaluation by an AlphaScreen biochemical assay (IC50). Finally, equilibrium 
dissociation constants (KD) were determined by isothermal titration calorimetry (ITC).  
  
  
 
Structure Activity Relationships. Earlier work. Previous SARs had identified phenyl sulfonamide 6 
as having reasonable binding affinity for all three BRPFs with a preference for BRPF1 (IC50 65 nM). 
These preliminary SARs were focussed on exploring three positions on this lead. The optimization of 
substituents on the phenyl ring of 6 identified a modest preference for a 4-CN group (7 << 6 ≈ 8 ≈ 9) 
and then modification of the groups at the N1 and C3 positions of the quinolin-2-one core showed that 
a 3-Me gave a significant increase in BRPF affinity leading to the discovery of 15.30 Hence, there was 
plenty of scope to further investigate this template with the aim of improving binding affinity for the 
BRPFs whilst reducing affinity for other BRDs, especially BRD9.  
Design principles. It was also important to retain the beneficial physicochemical properties of 6 (mw 
314; cLogP 2.0; tPSA 66; LE 0.46; LLE 5.2) by moderating the size and lipophilicity of new target 
compounds so as to be compatible with drug-like space. Additional guiding design principles were to 
avoid any reactive or potentially toxic groups, to have favourable biopharmaceutical properties, and to 
be chemically enabled. Modulation of these properties was achieved by the application of the lighter 
halogens (F), small alkyls (Me, Et, iPr), alkoxy (OMe, OEt, OiPr) and nitriles (CN) as substituents.  
This new phase of SAR investigation was directed at: (1) broader range of substitution of the 
sulfonamide, including reversing the connectivity (Table 2); (2) introduction of groups at each of the 
available positions on the quinolin-2-one core (Table 3); and (3) substitution of the NH of the 6-
sulfonamide (Table 4). In addition to optimizing for BRPF activity, we also aimed to identify specific 
points of SAR that would remove BRPF activity to generate a matched inactive control, and to provide 
selective hits for other BRDs of the class IV proteins.   
Simple sulfonamides. Simple alkyl sulfonamides 1-5 proved to be inferior to phenyl 6 with BRPF1 
activity tracking with increased lipophilicity of the alkyl substituent. Reversing the sulfonamide 
connection offered no advantage with a small set of benzonitriles 11-13 when compared to 7-9, 
although the 2-CN reversed sulfonamide 11 seemed to show a preference for BRD9 over BRPF1 in 
the DSF assay albeit with relatively modest ∆Tm values (Table 2).  
Sulfonamide substitution. Further exploration of the aryl sulfonamide ring when combined with the 
1,3-dimethylquinolin-2-one core identified our most potent BRPF inhibitors prepared so far (Table 3). 
Previously it had been shown that introduction of a 2-OMe 14 gave a potent inhibitor of BRPF1 
although with some unwanted BRD4 activity. In addition, the 4-CN group was a preferred single 
  
 
substituent or  could be combined with a second substituent at either the 2- or 3-position.30 Combining 
these points of SAR prompted the design and synthesis of the 2-OMe,4-CN analogue 16.  
Sulfonamide 16 showed improved BRPF1 activity in both the DSF and BROMOscan assays (BRPF1: 
∆Tm 12.3 oC; IC50 3.1 nM; mw 383; cLogP 2.1; tPSA 99; LE 0.44; LLE 6.4) and was superior to either 
the mono-substituted analogues 2-OMe (14) or 4-CN (15). This result prompted the routine 
exploration of both the 4-CN and 2-OMe,4-CN benzene sulfonamide analogues in compound design, 
and 16 was selected for further evaluation including BRPF1B co-crystal structure determination. 
The BRPF1B co-crystal structure with 16 was solved at 2.3 Å (Figure 2). Quinolin-2-one 16 fitted in 
the lysine acetylated-binding site of BRPF1B as expected, maintaining the conserved H-bond 
interaction with Asn708 and the water mediated H-bond with Tyr665. Additional key contacts specific 
of the core scaffold included a parallel and face-centered - stacking interaction of Phe714 side 
chain with the quinolin-2-one moiety at approximately 3.7 Å. Moreover, the phenyl rotamer was 
pointing towards the benzonitrile ring at 3.9 Å forming a CH- interaction. Embedded into the 
hydrophobic and non-charged binding site, the shape complementarity of 16 to the protein interface 
was high (Figure 2a). Further compound stabilization was observed by means of a water mediated 
bridge interaction between the sulfonamide and the 2-MeO group of the benzonitrile. Interestingly, an 
overlay of 16 with NI-48 (66) 30 showed a flip of 180º of the quinolin-2-one core with the N1-Me group 
pointing towards Tyr707 (Figure 2d and S2). This new scaffold conformation presented the lowest B-
factor values during compound fitting and refinement. This flip forced the benzonitrile group to move 
closer to the ZA-loop (Ile652). 
  
 
 
  
Figure 2. X-ray crystal structure of 16 (green) bound to BRPF1 (grey) (5MYG.pdb). (a) Electrostatic 
potential surface represented at the bromodomain binding site. (b) Close-up view of the interactions of 
16 with the BRPF1 binding site displayed in cartoon and sticks. (c) 2Fo − Fc electron density map 
contoured at 1σ showing electron density around 16. The figure shows the map for the fully refined 
structure. (d) Structural superposition of 16 with 66 (purple; 5T4V.pdb) in complex with BRPF1B. 
 
 
NI-48 (66) 
 
Quinolin-2-one substitution. Introduction of a limited number of single groups at specific positions on 
the quinolin-2-one core showed some advantage over hydrogen (e.g. 4-Me (21); 7-OMe (24) ≥ H (9)) 
but failed to improve BRPF1 activity to the same level as was achieved with a 3-Me substituent (15) 
(Table 3). Larger alkyls at C3 such as 3-Et (17, 18) or 3-iPr (19, 20) significantly reduced BRPF 
activity whereas groups at the 5-position (5-F (22); 5-OMe) were tolerated. Small alkoxy groups at C7 
  
 
showed a modest beneficial effect with 23-26 and so a 7-OMe was combined with the 3-Me group on 
the quinolin-2-one core to see if these effects were additive. 
A set of 6 preferred sulfonyl chlorides 56 were coupled with 6-amino-7-methoxy-1,3-dimethylquinolin-
2(1H)-one (53) to give the corresponding sulfonamides 28-33 (Table 3). These sulfonyl chlorides were 
selected based on previous beneficial SAR and extrapolation to close analogues. Compounds 28-33 
were all found to bind to BRPF1 with strong affinity as measured by DSF (∆Tm >8 oC) and 32 was 
selected as a representative example from this set for further evaluation based on its excellent 
potency (BRPF1: ∆Tm 12.7 oC; IC50 12 nM).      
Previously it has been shown that increasing the size of the alkyl groups flanking the quinolinone C2-
carbonyl would prevent binding to the BRPFs (and other BRDs) by disrupting the key recognition 
interaction between the carbonyl with Asn708 and the Tyr665 water network. This was most 
successfully achieved with ethyl groups at both the N1 and C3 positions which produced 36 as a 
matched inactive control for 15. Applying this strategy to lead 16 by the introduction of the N1-Et and 
3-Et groups gave 37 which still retained some modest BRPF1 activity (IC50 250 nM) (Table 3) with 
only an 80-fold drop in BRPF1 inhibition so as to be unsuitable as a negative control. This level of 
BRPF1 activity for 37 was somewhat surprising to us and difficult to explain based on our current 
understanding of the binding modes of these inhibitors (cf 16 and 66). Ultimately, this will need to be 
resolved by the determination of a BRPF1-37 co-crystal structure.  
N-Alkyl sulfonamides. The N-alkylation of the sulfonamide was detrimental to BRPF1 activity (Table 
4). It was found across several structures that the introduction of a N-Me on the sulfonamide group 
generally reduced BRPF1 activity by 20-fold (38 vs 9, 39 vs 24). Applying this approach to 16 gave N-
Me analogue 40 which also showed a 15-fold reduction in BRPF1 inhibition but 40 still showed 
significant BRPF1 inhibition (IC50 52 nM). Increasing the size of the N-alkyl group to N-Et (41) and N-
iPr (42) did reduce further BRPF1 activity by 35-fold and 50-fold respectively showing some additional 
disruption to binding but again not to a level to provide a credible negative control.  
 
Structural insights of 16 in complex to BRPF1B led us to understand the lower affinity for these N-
alkyl analogues for BRPF1. We examined all four molecules crystallized at the asymmetric unit of the 
orthorhombic crystal form. Overall, the NH of the sulfonamide group is facing towards the Glu661 
  
 
residue of the ZA loop. Distances from the NH group to the glutamic acid lipophilic side chain or the 
carboxylic group ranged between 3.6 – 4.3 Å limiting the space to accommodate bulky substituents 
(Figure S3). Additionally, Glu661 adopts a closed conformation as a result of a water mediated H-
bond interaction with a S(=O) of the sulfonamide group of 16.  
 
Inactive control. The SARs for a partnered inactive control would suggest that further increasing the 
size of the 3-alkyl to a 3-iPr (cf 16 vs 18 vs 20) in combination with a N1-Et (or N1-iPr) would further 
reduce the BRPF1 activity. A complementary approach to reduce BRPF activity was by substitution of 
the NH of the 6-sulfonamide (cf 16 vs 40-42). However, these SARs seemed to converge on the 
addition of two or more larger lipophilic groups at either N1, C3 and/or SO2NH positions to completely 
remove BRPF1 activity; these modifications were likely to yield compounds with minimal similarity to 
the active partner 16 in terms of chemical structure, molecular and physicochemical properties, and 
so were not pursued. On balance, compound 36 (NI-198)30 represents the best available matched 
inactive control for both 15 and 16.  
Preferred compounds. Completing the evaluation of preferred leads 16 and 32 against BRD1 and 
BRPF3 showed both compounds had potent activity against all three BRPFs with 16 having a slight 
advantage (Table 5). However, 16 showed a clear advantage over 32 when evaluated in the BRD9 
and BRD4(BD1) selectivity counter screens. Compound 16 had good selectivity over both BRD9 
(160-fold) and BRD4 (1200-fold) in the BROMOscan assay which was also superior to 15. In contrast, 
32 had poor selectivity compared to 16 with only 14-fold over BRD9 and 140-fold over BRD4. Non-
BET BRD inhibitors need to demonstrate excellent selectivity over BRD4 because of the dominant 
phenotype of this protein in cellular models and the narrow window of selectivity of 32 over BRD4 
activity could potentially confound interpretation of biological results. The low level promiscuous 
nature of 32 was further confirmed by a full BRD profile of 32 by DSF with 6 non-class IV proteins 
having binding ∆Tm in the range 2-3 oC (10 M) including several members of the BET family (Table 
S1). The erosion of selectivity for 32 was a combination of weaker activity for BRPF1 and increase 
activity for the other BRDs.  
Hence 16 emerged as the superior compound from this set suitable for further evaluation as a 
potential chemical probe for the BRD of the BRPFs. 
  
 
Improved Synthesis of 16. Once 16 had been identified as a potentially superior compound, the 
need for larger amounts of material to support SAR and biological studies prompted the development 
of an improved synthesis of both 6-amino-1,3-dimethylquinolin-2(1H)-one (44)30 and 4-cyano-2-
methoxybenzenesulfonyl chloride (65)37 (Scheme 3). A reliable synthesis of 65 initially proved to be 
somewhat problematic as, to date, there had been no published preparations for 65 and our original 
approaches to the synthesis of 65 were flawed. Only the diazotization of 4-amino-3-
methoxybenzonitrile then treatment with aqueous SO2-HCl gave modest yields of 65.38  
We developed an efficient synthesis of sulfonyl chloride 65 from 4-hydroxy-3-methoxybenzonitrile (61) 
utilising a thermal Newark–Kwart rearrangement39 (62 to 63) and then KOH hydrolysis of the 
carbamothioate 63 to thiol 64, followed by a zirconium(IV) chloride promoted oxidative chlorination 
reaction40 as the key steps.37 High purity 65 could be obtained by recrystallization from a mixed 
solvent system of toluene-hexane, however the crude material obtained directly from the reaction was 
found to be sufficiently pure to form sulfonamides in high yields. Simply filtering the acetonitrile 
solution of crude 65 directly from the reaction flask into a second receiving flask containing a solution 
of amine 44 and DABCO in DMF produced 16 in a good yield comparable to the 2-step process with 
recrystallized 65.   
  
  
 
Scheme 3: Synthesis of 65 and 16. 
 
Reagents and Conditions: (a) ClC(S)NMe2 (1.0 eq), DABCO (1.05 eq), DMF, 50 oC, 4 h, 76 %; (b)  
200 oC, 3 h,  94 %; (c) KOH (3.0 eq), MeOH, 30 oC, 12 h, 95 %; (d) ZrCl4 (1.0 eq), 30 % H2O2 (3.0 
eq), MeCN, 0 oC, 0.5 h, 92 %; (e) 6-amino-1,3-dimethylquinolin-2(1H)-one (44) (0.95 eq), DABCO (1.0 
eq), DMF, rt, 6 h, 76 %. 
  
  
 
Table 2. BRPF1 SAR of the 6-sulfonamide. 
         
1-5     6-9    10-13  
Compound R or X BRPF1 
 ∆Tm shift at 
10 M (oC) 
IC50 (nM)a 
 
1 
2 
3 
4 
5 
 
6 
7 
8 
9 
 
Me 
Et 
iPr 
cPr 
cHex 
 
H 
2-CN 
3-CN 
4-CN 
 
1.4 
1.8 
2.2 
1.9 
3.9 
 
5.3 
2.4 
4.4 
5.2 
 
 
2200 
1200 
1100 
520 
380 
 
65 
430 
56 
43 
 
10 
11b 
12 
13 
H 
2-CN 
3-CN 
4-CN 
 
3.5 
2.6 
2.3 
3.1 
1000 
 
 
100 
 
a BROMOscan BRD IC50 values are geometric means of two experiments 
(n=2). Differences of <2-fold should not be considered significant. b 
BRD9, ∆Tm (10 M) = 3.9 oC. 
  
  
 
Table 3. BRPF1 SAR of substitution on the quinolin-2-one. 
   
14-35      36, 37 
Compound Rx X BRPF1 
  ∆Tm shift at 
10 M (oC) 
IC50 (nM)a 
     
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
 
28 
29 
30 
31 
32 
33 
34 
35 
 
36 
37 
3-Me 
3-Me 
3-Me 
3-Et 
3-Et 
3-iPr 
3-iPr 
4-Me 
5-F 
7-OMe 
7-OMe 
7-OEt 
7-OiPr 
7-F 
 
3-Me,7-OMe 
3-Me,7-OMe 
3-Me,7-OMe 
3-Me,7-OMe 
3-Me,7-OMe 
3-Me,7-OMe 
3-Me, 8-F 
3-Me, 8-F 
 
 
2-OMe 
4-CN 
2-OMe,4-CN 
4-CN 
2-OMe,4-CN 
4-CN 
2-OMe,4-CN 
4-CN 
4-CN 
H 
4-CN 
4-CN 
4-CN 
4-CN 
 
H 
2-OMe 
4-CN 
2-Me,4-CN 
2-OMe,4-CN 
2-OEt,4-CN 
4-CN 
2-OMe,4-CN 
 
4-CN 
2-OMe,4-CN 
 
10.2 
9.7 
12.3 
5.6 
8.0 
 
 
4.3 
2.7 
6.3 
5.6 
 
 
3.8 
 
9.4 
11.0 
8.8 
9.9 
12.7 
9.5 
7.1 
6.8 
 
9.0 
7.9b 
3.1 
180 
93 
870 
170 
24 
 
29 
53 
55 
39 
 
 
17 
 
15 
 
12 
 
 
12 
 
>100,000 
250 
 
a BROMOscan BRD IC50 values are geometric means of two experiments (n = 2). 
Differences of <2-fold should not be considered significant.  b n = 4. 
  
  
 
Table 4. BRPF1 SAR at the N-sulfonamide position. 
  
 38-42  
Compound RN R3 or 7 X BRPF1 
   ∆Tm shift at 
10 M (oC) 
IC50 (nM)a 
 
38 
39 
40 
41 
42 
 
Me 
Me 
Me 
Et 
iPr 
 
H 
7-OMe 
3-Me 
3-Me 
3-Me 
 
4-CN 
4-CN 
2-OMe,4-CN 
2-OMe,4-CN 
2-OMe,4-CN 
 
1.8 
 
7.1 
 
 
 
 
910 
1000 
52 
110 
160 
 
a BROMOscan BRD IC50 values are geometric means of two experiments (n = 2). 
Differences of <2-fold should not be considered significant. 
  
  
 
Table 5: BRD selectivity profiles of N-methylquinolin-2(1H)-ones 
 
Compound 
IC50 (nM)a 
BRPF1 BRPF2 
(BRD1) 
BRPF3 BRD9 BRD4(BD1) 
 
      
6 65 1400 7600 2200 1700 
7 430 1700    
8 56 270    
9 43 200 1000 910 2800 
10 1000 7800 >100,000 9800 37,000 
13 100 150 2200   
14 9.0 130   600 
15 7.9 b 48 260 310 4500 
16 3.1 46 140 520 3700 
19 870 14,000 16,000   
20 170 3300 4600 9300  
21 24 150    
23 29 380 2200   
24 53 520 2200 2700 >10,000 
28 17 190 590   
30 15 100 280   
32 12 80 190 170 1700 
35 12 510 10,000   
36c >100,000 >100,000 >100,000 >100,000 >100,000 
37 250 4400 4600   
38 
 
910 6700    
 
 
a BROMOscan BRD IC50 values are geometric means of two experiments (n = 2). Differences of <2-fold should not be considered significant. 
b n = 4 
c BRD7, ATAD2A, ATAD2B, CREBBP, PCAF, BAZ2A, TRIM33, CECR2: BROMOscan BRD IC50 >100,000 nM. SMARCA2A: IC50 77,000 nM. See, reference 
30.  
  
 
Potency and selectivity of 16. Completing the evaluation of lead compound 16 against all members 
of the class IV family of BRDs in the BROMOscan assay identified affinity for BRD7 but was 
completely selective over the ATAD2s (Table 6; Figure S4). 16 was confirmed as a potent inhibitor of 
BRPF1 by independent evaluation in an AlphaScreen biochemical assay and with a very similar 
relative rank order of activities to other screening formats (Table 6).36 
Compound 16 was screened for BRD binding by DSF against a panel of 47 BRDs and showed 
excellent selectivity. All activity was confined to the class IV family of BRDs with ∆Tm < 1 oC 
stabilization for all non-class IV BRDs except TRIM24(2.0), CREBBP (1.1) and EP300 (1.1) (Figure 3; 
Table S1). 16 was also tested for BRD selectivity in the BROMOscan panel of 46 binding assays and 
showed all potent activity was confined to the class IV family (Table S2). Once again, TRIM24 was 
identified as the non-class IV BRD with most affinity (IC50 1600 nM) but still with a 500-fold window of 
selectivity.  
It is important to note that we did not observe any significant binding or inhibition of BRD4 across 
multiple orthogonal screening platforms (DSF, BROMOscan, AlphaScreen, FP) (Table 6). These 
results have been independently corroborated by a group at Bayer in a TR-FRET assay.29 
Compound 16 was then evaluated in a number of assays to establish the broader pharmacological 
selectivity and biopharmaceutical properties. 16 was screened for off-target pharmacology against a 
panel of 55 representative GPCRs, ion channels and enzymes (Eurofins, ExpresSProfile) and was 
found to have minimal inhibition (<40 % @ 10 M).36 Any cardiovascular risk was low as 16 showed 
minimal activity against a panel of 8 cardiac ion channels (<40% @ 30 μM) (Table S3). 16 has 
reasonable aqueous solubility and good cell permeability as measured by transit performance in the 
Caco2 cell line but with some evidence of efflux (Table 6). 16 has good metabolic stability in both 
MLM and HLM consistent with predicted low clearance, and weak CYP450 enzyme inhibition (Table 
S4). 
 
ITC data showed that 16 bound the BRD of BRPF1 with a KD of 31 ± 2 nM, BRD1 with a KD of 110 ± 
13 nM and BRPF3 with a KD of 410 ± 47 nM, whereas binding to BRD9 was weaker (KD 1000 ± 130 
nM) (Table 6).36 These data showed that 16 was more potent for the BRDs of BRPF1/2/3 and slightly 
more selective over BRD9 than 15.   
  
 
 
Figure 3. Selectivity profile of 16 assessed against 47 BRDs by thermal shift, ∆Tm (oC), at 10 M as 
measured by DSF (n = 2).  
 
 
 
 
  
  
 
Table 6: Summary of physicochemical properties, in vitro bromodomain 
inhibition, ITC screening and cell permeability of 16. 
 
16: NI-57 
Physicochemical properties 
mw      383 
ClogP      2.1 
tPSA (Å2)     99 
 
Bromodomain inhibition 
BRPF1/2/3   BROMOscan IC50 (nM) 3.1; 46; 140 
BRD7/9  BROMOscan IC50 (nM) 140; 520 
ATAD2A/2B BROMOscan IC50 (nM) >100,000; >100,000 
BRD4(BD1) BROMOscan IC50 (nM) 3700 
TRIM24 BROMOscan IC50 (nM) 1600 
 
 
BRPF1/2/3   AlphaScreen  IC50 (nM) 114; 619; 1010a 
BRD9    AlphaScreen  IC50 (nM) 4400b 
BRD4(BD1)   AlphaScreen  IC50 (nM) >10,000a 
TRIM24  AlphaScreen  IC50 (nM) >10,000a 
 
BRD4(BD1)   FP assay  IC50 (nM) >33,000c  
 
Bromodomain ITC  screening 
BRPF1/2/3  ITC   KD (nM)  31; 110; 410 
BRD9   ITC   KD (nM)  1000 
 
Solubility and cell permeability 
Aqueous solubility    moderate (100 M min)d 
Caco2 transit AB/BA, Papp (x10-6 cms-1)  11/52 
 
a  See reference 36.  
b  This work. 
c See Figure S5. 
d Maximum concentration used in screening assays created by serial dilution of a 100 mM stock 
solution of 16 in DMSO. 
 
  
  
 
Evidence of cellular activity. Cellular ‘on-target’ activity for 16 was assessed in a BRPF1B-
Histone3.3 nanoBRET assay which showed dose-dependent displacement of BRPF1B (but not 
BRPF1A) from Histone H3.3 with an estimated IC50 of 0.07 ± 0.0034 M. These results were verified 
in a FRAP assay where 16 displaced a triple BRD-BRPF1B-GFP fusion construct, as well as full 
length BRD1-GFP, which was demonstrated by significant reduction in recovery times in the presence 
of the inhibitor.36 Hence, the nanoBRET and FRAP experiments confirm 16 inhibit BRPF BRDs in the 
nucleus. 
 
Activity in phenotypic screens. BRD containing proteins are frequently dysregulated in cancer.41 
Previously, compound 15 has been evaluated in a panel of cancer cell lines and showed a modest 
inhibition of proliferation of certain AML lines, particularly those lines exhibiting monocytic lineage 
differentiation.30 Here we report additional studies that show 16 has functional activity in cellular 
assays by modulation of the phenotype (or markers) at low molar concentrations in both cancer and 
inflammatory models.  
Compound 16 was evaluated in two indexed panels of cancer cell lines: the NIH National Cancer 
Institute NCI-6042 and AstaZeneca’s CLIMB panel.43 Screening 16 in the NCI-60 panel showed 
minimal effects on inhibition of proliferation over 48 h with typically ≤ 25 % inhibition at 10M in these 
lines.  We subsequently treated the CLIMB panel with 16 for 72 h and observed modest and selective 
inhibition of proliferation of certain cell lines (Table 7). It is encouraging that, for these lines, both 15 
and 16 show a similar effect on inhibition of proliferation. The different outcomes in the two panel 
screens are not inconsistent as the responding cell lines in the CLIMB panel were not present in the 
NCI-60. These results highlight the value of wide profile screening in phenotypical assays in 
conjunction with hypothesis driven screening strategies. In addition, these BRPF BRD inhibitors 15 
and 16 had minimal effect on the proliferation of many cancer cell lines in the CLIMB panel (and other 
cell lines) suggesting they are not cytotoxic.30, 36 
  
  
 
Table 7. Examples of inhibition of proliferation of cancer cell lines (GI50) by 15 and 16.a 
  
Tissue 
GI50 (M) 
Cancer cell line 15 
 
16 
 
 
NCI-H1703 
DMS114 
HRA-19 
RERF-LC-Sq1 
 
~ 150 cell lines 
 
 
lung 
lung 
colon 
lung 
 
various 
 
>30 
16.6 
15.6 
17.1 
 
b 
 
 
10.4 
14.7 
15.6 
16.6 
 
>30 
 
a AstaZeneca CLIMB panel includes 211 cancer cell lines. 72 h proliferation assay; 9 point 
dose-response-curve with a highest concentration of 10 or 30 M (n = 2). For an example of 
the use of oncology cell panels in mechanistic and pathways analysis, see reference 43. b 
For a more complete profile of 15 in this panel, see reference 30. 
 
Small molecule chemical probes that modulate BRD proteins are being employed to reveal the role of 
epigenetics in guiding cell fate decisions during immune responses and have highlighted the potential 
of these approaches for the treatment of inflammatory and immune-related disease.44 Human 
macrophages are characterized by their remarkable plasticity and can be skewed towards a pro-
inflammatory phenotype upon LPS/IFNγ stimulation (100ng/ml), resulting in the production of pro-
inflammatory cytokines such as TNF (Figure 4A). On the opposite end of the macrophage activation 
spectrum, IL-4 (200ng/ml) induces a Type II inflammation phenotype characterized by the production 
of CCL-22 (Figure 4A).45,46 BRPF1 gene expression was significantly increased in IL-4-stimulated 
human alveolar macrophages (AM) in comparison to LPS/IFNγ-stimulated AM with a 1.7 ± 0.5 fold 
increase (Figure 4B). Blocking BRPF1 in the IL-4-stimulated AM with 16 (10 µM) decreased the gene 
expression of CCL-22 by 27.7 ± 9.4% (Figure 4C).  
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Figure 4.  Alveolar Macrophages (AM) were isolated from lung resections of non-smoker, ex-smoker 
and smoker subjects. Isolated AM were LPS/IFNγ-stimulated (100ng/ml) or IL-4-stimulated (200ng/ml) 
during 24h together with DMSO (●,  ●, respectively). Subsequently, TNF and CCL-22 (A) or BRPF1 
(B) gene expression were measured and plotted. Gene expression was relativised to untreated 
macrophages. (C)  IL-4 stimulated alveolar macrophages were treated with DMSO or 16 (●) and CCL-
22 gene expression was measured and plotted. Gene expression was relativised to DMSO treated 
macrophages. (* = p <0.05, Wilcoxon comparison test) 
 
M2-activated alveolar macrophages have been shown to play a role in the resolution of many lung 
inflammatory conditions, but can also contribute to different pulmonary diseases. Eosinophilic 
pneumonia and asthma have been associated with an increased CCL-22 production by alveolar 
macrophages.47,48 The observation that BRPF1 is involved in inducing CCL-22 production by alveolar 
macrophages could be of importance for the treatment of these pulmonary diseases.  
Taken together, these results provide evidence that 16 is functionally active in cellular assays although 
we have yet to prove that these effects are the direct consequences of the inhibition of the BRD of the 
BRPFs. Additional studies will be required to more fully establish the role of 16 and the BRPFs in 
cancer and inflammation including demonstration of on-target effects and target confirmation in 
disease relevant cell models. These studies are ongoing by this group and will be reported in due 
course. 
In an associated Article, we explore functional consequences of inhibitors targeting BRDs present in 
BRPFs in bone maintenance. We report three complementary potent and selective inhibitors: one with 
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high selectivity for the BRPF1B isoform,25 and two structurally different pan-BRPF BRD inhibitors.24 
The inhibitors impaired RANKL-induced differentiation of primary murine bone marrow cells and 
human primary monocytes into bone resorbing osteoclasts by repressing transcriptional programs. 
The data suggest a key role of BRPF in regulating gene expression during osteoclastogenesis. These 
studies will be reported separately.36 
 
In vivo Pharmacokinetics. PK data for 16 was generated in vivo in mouse (Table S4). Following 
single intravenous administration of 16, clearance was low relative to liver blood flow and volume of 
distribution was moderate resulting in an elimination half-life of 1.2 h. Single oral administration of 16 
as a suspension showed favourable oral bioavailability of 29 %. The fraction absorbed was calculated 
to be 35 % based on the measured blood clearance and oral bioavailability values. 
  
  
 
CONCLUSION  
We have designed and evaluated a number of new quinolin-2-one derivatives as inhibitors of BRPF 
BRD activity. Previous SARs had identified phenyl sulfonamide 6 as having reasonable binding 
affinity for all three BRPFs with a preference for BRPF1 (IC50 65 nM). This new phase of detailed SAR 
studies showed that a broader range of substitution of the phenyl ring of the sulfonamide could be 
accommodated with 4-CN and 2-OMe,4-CN groups preferred. Introduction of groups at each of the 
available positions on the quinolin-2-one core showed some advantage over hydrogen but failed to 
improve BRPF1 activity to the same level as had been achieved with a 3-Me substituent (15). The 
combination of the preferred substituents on the sulfonamide ring with the 1,3-dimethylquinolin-2-one 
core gave 16 as our most potent BRPF1 inhibitor (IC50 3.1 nM). Additional screening of 16 showed 
potent binding affinity for all three BRPFs with good selectivity over BRD9 and BRD4. The binding of 
16 to BRPF1 was rationalized through an X-ray co-crystal structure determination which showed a 
flipped binding orientation of the quinolin-2-one in the Ac-Lys pocket when compared to previous 
structures. 
Compound 16 was then evaluated in a number of assays to establish the broader pharmacological 
selectivity. 16 showed excellent selectivity in panels of BRDs with all potent activity confined to the 
class IV family of BRDs and minimal off-target pharmacology against a panel of representative 
GPCRs, ion channels and enzymes. ITC data confirmed that 16 preferentially bound the BRD of 
BRPF1 and BRD1 over BRPF3 whereas binding to BRD9 was weaker. Based on these results, 16 
was identified as a potent inhibitor of the BRD of the BRPFs with excellent selectivity over non-class 
IV BRD proteins. BRPF1 target engagement in living cells with 16 was demonstrated in both 
nanoBRET and FRAP assays.  
 
Evaluation of 16 in a panel of cancer cell lines showed a modest (GI50 10-16 M) and selective 
inhibition of proliferation of certain lines. In addition, 16 decreased the expression of M2-associated 
genes, such as CCL-22, in human alveolar macrophages. These results provide clear evidence that 
16 has activity in cellular assays. However, additional studies will be required to fully establish the role 
of 16 and the BRPFs in disease models.  
  
 
Pharmacokinetic data for 16 was generated in vivo in mouse with single oral administration of 16 as a 
suspension showing favourable oral bioavailability. These results established that 16 had PK 
properties compatible with oral dosing in mouse models of disease.  
In conclusion, we propose that 16 (NI-57)36 is a new pan-BRPF chemical probe for BRD of the BRPFs 
suitable for cellular and in vivo studies to explore the fundamental biology of these proteins. 
Compound 16 has good selectivity over both BRD9 (160-fold) and BRD4 (1200-fold) in the 
BROMOscan assay which is superior to 15 (39-fold and 570-fold respectively), although the BRD9 
selectivity is eroded somewhat in the ITC screen. Ultimately the merits of 15 and 16 will be 
established by their relative utility in both biochemical assays and performance in phenotypical 
screens. Preliminary results with these chemical probes in number of cellular models are helping to 
establish a possible link between the BRPF proteins and disease.  
  
 
EXPERIMENTAL SECTION 
 
Chemistry methods and compound characterization data for 16. 
General Methods:  
All anhydrous solvents and reagents were obtained from commercial suppliers and used without 
further purification. Flash chromatography refers to medium pressure silica gel (C60 (40-60 μm)) 
column chromatography, unless otherwise stated. The progress of reactions was monitored by thin 
layer chromatography (TLC) performed on Keiselgel 60 F254 (Merck) silica plates and visualised by 
exposure to UV light at 254 nm. 
Melting points (mp) were determined in open capillary tubes on a Stuart SMP10 apparatus and are 
uncorrected. Infrared (IR) analysis was performed on a Perkin Elmer Spectrum 1000 FT-IR in the 
4000-400 cm-1 range. 1H Nuclear Magnetic Resonance (1H NMR) spectra were recorded on a Bruker 
Advance 400 Spectrophotometer at 400 MHz or Bruker Advance 500 Spectrophotometer at 500 MHz. 
Chemical shifts were measured in parts per million (ppm) relative to tetramethylsilane (δ = 0) using 
the following internal references: CDCl3 (δ 7.26), CD3OD (δ 3.32), DMSO-d6 (δ 2.50). Multiplicities in 
1H NMR spectra are quoted as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = 
double doublet, ddd = double double doublet. 13C Nuclear Magnetic Resonance (13C NMR) spectra 
were recorded on a Bruker Advance 500 Spectrophotometer at 125 MHz. Chemical shifts were 
measured in parts per million (ppm) relative to tetramethylsilane (δ = 0) using the following internal 
references: CDCl3 (δ 77.16), CD3OD (δ 49.00), DMSO-d6 (δ 39.52). 2D NMR techniques HSQC, 
HMQC and HMBC were also utilised for the assignment of 1H and 13C NMR signals. High-resolution 
mass spectra (HRMS) were recorded on a Thermo Navigator mass spectrometer coupled to an HPLC 
instrument using electrospray ionisation (ESI) and time-of-flight (TOF) mass spectrometry. 
Alternatively, HRMS were recorded at the EPSRC UK National Mass Spectrometry Facility (NMSF) at 
Swansea University. Analytical reverse-phase high-performance liquid chromatography (HPLC) was 
carried out on a XSELECT™ CSH™ C-18 column (2.5 μm; 6 x 50 mm). HPLC experiments (system 
A) were performed with gradient conditions: initial fixed composition 5% B to 50% B over 20 min, then 
increased to 95% B over 2 min, held for 2 min at 95% B, then returned to 5% B in 1 min. Total 
duration of gradient run was 25 min. Eluents used were solvent A (H2O with 0.02% TFA) and solvent 
B (MeCN with 0.02% TFA). Flow rate: 1.00 mL/min. 
  
 
Purity of screening compounds 1-42 was evaluated by NMR spectroscopy and HPLC analysis. All 
compounds had purity ≥ 95 % by HPLC.  
Compound 16 is commercially available from Tocris (cat no. 5786), Cayman (17662), Sigma-Aldrich 
(SML-1486) and other suppliers.  
 
4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesuolfonamide (16): 
A 500 mL round bottom flask A charged with 6-amino-1,3-dimethylquinolin-2(1H)-one (44)30 (3.25 g, 
17.3 mmol, 0.95 eq.) and 1,4-diazabicyclo[2.2.2]octane (2.10 g, 18.7 mmol) 1.0 eq.) was evacuated 
and back-filled with nitrogen three times.  Anhydrous DMF (40 mL) was added and the solution stirred 
until all solids had dissolved. 
Separately, a 250 mL three-necked round bottom flask B fitted with a reflux condenser and internal 
thermometer was charged with 4-mercapto-3-methoxybenzonitrile (64)37 (3.0 g, 18.2 mmol, 1.0 eq.) 
and zirconium(IV) chloride (4.2 g, 18.2 mmol, 1.0 eq.) before being evacuated and back-filled with 
nitrogen gas three times. Anhydrous acetonitrile (90 mL) was added by syringe and the reaction 
mixture stirred until homogeneous.  The reaction mixture was cooled to 0 °C and then hydrogen 
peroxide (30% w/w aqueous, 5.4 mL, 54.5 mmol, 3.0 eq.) was added dropwise keeping the internal 
temperature below 10 °C. [CAUTION. The reaction is highly exothermic, as such monitoring the 
internal temperature during the addition of the hydrogen peroxide is important in order to avoid 
thermal runaway]. During the hydrogen peroxide addition, the solution was noted to become turbid 
before returning to a homogenous state.  The reaction mixture was maintained at 0 °C and stirred for 
a further 0.5 hours, during this time a white precipitate was observed to form.  Stirring was then 
stopped and the precipitate was allowed to settle on the bottom of the flask.  The freshly formed 
solution of 4-cyano-2-methoxybenzenesulfonyl chloride (65) in acetonitrile was then transferred by 
cannula into the stirred DMF solution of 44 in flask A.  During the addition, a white mist was observed 
to form in the flask that dissipated after about 10 minutes.  The remaining solid in the emptied flask B 
was washed with an additional 20 mL of anhydrous acetonitrile and the supernatant was again 
transferred by cannula into the receiving flask A.  The resultant heterogeneous reaction mixture was 
stirred for a further 6 hours at room temperature after which time all of 44 was consumed. The 
reaction mixture was then poured into a one litre conical flask containing ice-cold hydrochloric acid 
  
 
(1.0 M, 200 mL) and stirred for 0.5 hours.  The off-white precipitate was then collected onto a glass 
sintered-funnel, washed with two portions of cold ethanol (50 mL) and dried overnight to give 16 (5.04 
g, 76 %) as an off-white solid. Mp 246-247 oC; 1H NMR (500 MHz, DMSO-d6): δ 10.30 (s, 1H), 7.86 
(d, J = 8.2 Hz, 1H), 7.74 (d, J = 1.3 Hz, 1H), 7.70 (s, 1H) 7.47 (dd, J = 7.9, 1.3 Hz, 1H), 7.38 (d, J = 
8.8 Hz, 1H) 7.31 (d, J = 2.2 Hz, 1H), 7.26 (dd, J = 7.9, 1.3 Hz, 1H), 3.98 (s, 3H), 3.55 (s, 3H), 2.09 (s, 
3H); 13C NMR (125 MHz DMSO-d6): δ 161.3, 156.3, 135.9, 135.0, 131.1, 130.7, 129.9, 124.1, 122.9, 
120.2, 119.0, 117.5, 116.8, 116.7, 115.3, 59.6, 29.4, 17.3; HRMS: m/z ESI+ Found (M+H)+ 384.1013. 
C19H17N3O4S requires (M+H)+ 384.0940; HPLC: Retention time (system A): tR= 6.04 min. Purity: 
>95%. 
O-(4-Cyano-2-methoxyphenyl) dimethylcarbamothioate (62): To a 500 mL three-necked round 
bottom flask fitted with a 100 mL pressure-equalised dropping funnel and internal thermometer was 
added 4-hydroxy-3-methoxy-benzonitrile (61) (25.0 g, 168 mmol, 1.0 eq.) followed by 1,4-
diazabicyclo[2.2.2]octane (19.8 g, 176, 1.05 eq.).  The system was next flushed with nitrogen and 
anhydrous DMF (100 mL) added via syringe.  The slurry was warmed to 50 °C during which time it 
became an homogenous brown solution.  In the interim, a solution of dimethylcarbamoyl chloride 
(20.7 g, 168 mmol, 1.0 eq.) in anhydrous DMF (30 mL) was prepared in a 100 mL round bottom flask 
at room temperature and transferred to the dropping funnel.  The solution of dimethylcarbamoyl 
chloride was next added dropwise to the reaction mixture over a period of 10 minutes and the mixture 
stirred for a further 4 hours at 50 °C.  The reaction mixture was next cooled to room temperature and 
water (2 x 75 mL) added via the dropping funnel.  After approximately 75 mL of water had been 
added, large scale precipitation of the desired product was observed along with a modest 10 °C 
exotherm.  After all of the water had been added, the resultant slurry was stirred for a further 0.5 
hours before the product was collected by filtration onto a sintered-glass funnel. The white crystals 
were washed with cold water (2 x 50 mL) and dried under vacuum.  The product was collected to give 
pure 62 as white crystals (30.2 g, 76 %). Mp 127-128 oC;  1H NMR (500 MHz, CDCl3): δ 7.31 (d, J = 
8.2 Hz, 1H), 7.21 (s, 1H), 7.14 (d, J = 8.2 Hz, 1H), 3.87 (s, 3H), 3.46 (s, 3H), 3.37 (s, 3H); 13C NMR 
(125 MHz, CDCl3): δ 186.6, 152.2, 146.5, 125.3, 125.2, 118.5, 115.8, 110.5, 56.3, 43.5, 38.9. 
S-(4-Cyano-2-methoxyphenyl)dimethylcarbamothioate (63): To a 250 mL three-necked round 
bottom flask fitted with a reflux condenser was added O-(4-cyano-2-methoxyphenyl) 
  
 
dimethylcarbamothioate (62) (29.0 g, 115 mmol, 1.0 eq.). The flask was evacuated and back-filled 
with nitrogen gas three times and then heated at 200 °C on a DrySyn heating block. After 3 hours the 
reaction mixture was allowed to cool to around 150 °C before toluene (50 mL) was added via syringe.  
The reaction mixture was allowed to further cool to around 90 °C and a further portion of toluene (50 
mL) was added along with a magnetic stir-bar.  The reaction mixture was then allowed to cool to room 
temperature and stirred overnight, during which time the desired product precipitates as colourless 
crystals.  The precipitate was collected by filtration onto a sintered-glass funnel, washed with cold 
toluene (2 x 50 mL) and dried under vacuum to give analytically pure 63 (27.2 g, 94%). Mp 150-151 
oC;  1H NMR (500 MHz, DMSO-d6): δ 7.60 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.43 (d, J = 
7.8, 1.8 Hz, 1H), 3.85 (s, 3H), 3.15–2.83 (br m, 6H); 13C NMR (500 MHz, DMSO-d6): δ 163.2, 159.4, 
138.0, 124.3, 123.5, 118.4, 114.9, 113.2, 56.6, 39.5. 
4-Mercapto-3-methoxybenzonitrile (64): To a 250 mL round bottom flask was charged S-(4-cyano-
2-methoxyphenyl)dimethylcarbamothioate (63) (15.7 g, 66.8  mmol, 1.0 eq.) followed by methanol 
(100 mL).  To the stirred slurry, was added potassium hydroxide flakes (11.2 g, 200 mmol, 3.0 eq.) 
portionwise.  The reaction was warmed to 30 °C and stirred for 12 hours.  The homogenous reaction 
mixture was then diluted with ethyl acetate (200 mL) and acidified to pH 2 with 3.0 M hydrochloric 
acid.  Sufficient water was then added until any salt precipitate had re-dissolved.  The phases were 
separated and the aqueous layer extracted with ethyl acetate (2 x 200 mL).  The combined organic 
phases were washed with brine (300 mL), dried over anhydrous magnesium sulfate and then 
concentrated under reduced pressure to give 64 (10.6 g, 96 %) as a slightly pungent off-white solid. 
Mp 66-67 oC; 1H NMR (400 MHz, CDCl3): δ 7.32 (d, J = 7.8 Hz, 1H), 7.16 (dd, J = 7.8, 1.5 Hz, 1H), 
7.05 (d, J = 1.5 Hz, 1H), 4.12 (s, SH), 3.93 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 154.3, 129.2, 129.0, 
125.0, 118.9, 113.0, 109.1, 56.3. 
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ABBREVIATIONS USED 
AM, alveolar macrophages; AML, acute myeloid leukemia; ATAD2, ATPase family, AAA domain 
containing; BAZ2A, bromodomain adjacent to zinc finger domain protein 2A; BRD4(BD1), 
bromodomain containing protein 4, first bromodomain; BET, bromodomain and extra terminal domain; 
BRD, bromodomain containing protein; BRET, bioluminescence resonance energy transfer; BRPF, 
bromodomain and PHD finger-containing; CLIMB, Cell Lines Indexed for Molecular Biology; CREBBP, 
CREB-binding protein; CYP450, cytochrome P450; DABCO, 1,4-diazabicyclo[2.2.2]octane; DSF, 
  
 
differential scanning fluorimetry; DMF, N,N-dimethyl formamide; EP300, E1A binding protein p300; 
EAF6, EAS1-associated factor 6; EPC, enhancer of polycomb; FP, fluorescence polarization; FRAP, 
fluorescence recovery after photobleaching; GPCR, G-protein-coupled receptor; HAT, histone acyl 
transferase; HLM, human liver microsomes; IFN, interferon gamma; IL-4, interleukin-4; ING, inhibitor 
of growth family; ITC, isothermal titration calorimetry; LE, ligand efficiency = 1.4(-log IC50)/number of 
heavy atoms; LLE, lipophilic ligand efficiency = (-log IC50) - clogP; LPS, lipopolysaccharide; MLM, 
mouse liver microsomes; MYST, MOZ, Ybf2/Sas3, SAS2 and Tip60; PCAF, P300/CBP-associated 
factor; PHD, plant homeodomain; PK, pharmacokinetic; PWWP, Pro-Trp-Trp-Pro; SAR, structure 
activity relationship; SMARCA2, SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily A, member 2; TAF1, transcription initiation factor TFIID subunit 1; TNF, tumor 
necrosis factor; tPSA, topological polar surface area; TR-FRET, time-resolved fluorescence energy 
transfer; TRIM24, tripartite motif containing 24; WPF, Trp-Pro-Phe.  
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Figure 1. Cartoon representation of BRPFs as part of the tetrameric MYST scaffolding complex along 
with ING5 and hEAF6. The BRPFs contain multiple chromatin reader domains. 
  
V 
EPL1 PWWP BRD 
BRPF1/2/3 
hEAF6 
ING5 
KAT6A/B 
PHD1 PHD
Zn knuckle 
H2AK5ac 
H3K14ac 
H4K12ac 
  
 
 
 
Figure 2. X-ray crystal structure of 16 (green) bound to BRPF1 (grey) (5MYG.pdb). (a) Electrostatic 
potential surface represented at the bromodomain binding site. (b) Close-up view of the interactions of 
16 with the BRPF1 binding site displayed in cartoon and sticks. (c) 2Fo − Fc electron density map 
contoured at 1σ showing electron density around 16. The figure shows the map for the fully refined 
structure. (d) Structural superposition of 16 with 66 (purple; 5T4V.pdb) in complex with BRPF1B. 
  
  
 
 
Figure 3. Selectivity profile of 16 assessed against 47 BRDs by thermal shift, ∆Tm (oC), at 10 M as 
measured by DSF (n = 2).  
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Figure 4.  Alveolar Macrophages (AM) were isolated from lung resections of non-smoker, ex-smoker 
and smoker subjects. Isolated AM were LPS/IFNγ-stimulated (100ng/ml) or IL-4-stimulated (200ng/ml) 
during 24h together with DMSO (●,  ●, respectively). Subsequently, TNF and CCL-22 (A) or BRPF1 
(B) gene expression were measured and plotted. Gene expression was relativised to untreated 
macrophages. (C)  IL-4 stimulated alveolar macrophages were treated with DMSO or 16 (●) and CCL-
22 gene expression was measured and plotted. Gene expression was relativised to DMSO treated 
macrophages. (* = p <0.05, Wilcoxon comparison test) 
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Chemical structure as .gif 
Size requirements: less than 21.0 x 5.5 cm 
 
 
 
 
BRPF1 BRD KD  =    31 nM 
BRPF2 BRD KD  =  110 nM 
BRPF3 BRD KD  =  410 nM 
 
 
 
 
pan-BRPFs chemical probe flipped binding mode selective over non-class IV BRDs 
 
